"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to offer IGIB's expertise in genome manipulation towards translational efforts in this area", said Dr. Anurag Agrawal, Director, CSIR-IGIB at the inking of the agreement with Cellogen Therapeutics.from Industry-Economic Times
Read The Rest:economictimes...
